Second-Line Nivolumab Data in mUC Show Efficacy as FDA Considers Approval
October 9th 2016Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency applications were reported at the 2016 ESMO Congress.
Read More
Regorafenib Shows Clinical Benefit in Patients with HCC Who Progress on Sorafenib
October 8th 2016The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma who are unsuitable for loco-regional therapy and have progressed on sorafenib.
Read More
SIRT Improves Depth of Response in mCRC Patients With Liver Mets
July 1st 2016Adding selective internal radiation therapy with SIR-Spheres Y-90 resin microspheres to standard first-line chemotherapy significantly increased hepatic depth of response in patients with metastatic colorectal cancer.
Read More
Higher Cytokine Levels Improve Nivolumab Efficacy in Squamous NSCLC
April 16th 2016Efficacy and safety remained strong 2 years following treatment with nivolumab for patients with advanced, refractory, squamous non-small–cell lung cancer, with an indication that cytokine levels could predict long-term outcomes.
Read More
Update Identifies Best Responders to Necitumumab in NSCLC
April 15th 2016Adding necitumumab to conventional chemotherapy improved outcomes in patients with metastatic squamous non–small cell lung cancer in the phase III SQUIRE trial, but the greatest benefit was derived by patients with EGFR-expressing tumors.
Read More
Fosaprepitant Improves Emesis Control in Women Receiving Chemoradiotherapy for Cervical Cancer
September 28th 2015Adding fosaprepitant (Emend) to an antiemetic regimen significantly improved emesis control versus standard care in women receiving radiotherapy and cisplatin for cervical cancer.
Read More
Atezolizumab Provides Viable Treatment Option in Metastatic Urothelial Carcinoma
September 27th 2015Second-line atezolizumab demonstrated significant clinical benefit in patients with metastatic urothelial carcinoma who had a poor prognosis after progressing following platinum-based chemotherapy.
Read More
Second-Line Cetuximab Shows PFS Benefit in Wild-Type mCRC
July 4th 2015Patients with metastatic colorectal cancer benefited from treatment with cetuximab plus chemotherapy even after disease progression on a similar regimen as long as their tumors did not harbor mutations in any of four key genes.
Read More
Survival Benefit of Regorafenib Confirmed in Combined Analysis of CORRECT and CONCUR
July 4th 2015The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.
Read More
Improved OS, PFS Demonstrated by TAS-102, Regardless of KRAS Status
July 3rd 2015TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.
Read More
Hepatitis C "Revolution" May Transform Liver Cancer Outcomes
July 2nd 2015Novel agents that target the replication of the hepatitis C virus are poised to have a far-reaching impact on the prevention and recurrence of hepatocellular carcinoma and have shown the ability to reverse liver fibrosis, including cirrhosis in patients with end-stage HCC.
Read More
Low BMI Prognostic for Worse Survival in Colorectal Cancer
July 1st 2015Results from a pooled dataset of more than 6000 patients with metastatic colorectal cancer found an association between low body mass index and a worse median overall survival with first-line bevacizumab and chemotherapy, suggesting that low BMI could be a prognostic factor for worse outcomes.
Read More